Plitidepsin as a successful rescue treatment for prolonged viral SARS-CoV-2 replication in a patient with previous anti-CD20 monoclonal antibody-mediated B cell depletion and chronic lymphocytic leukemia

Autor: P. Guisado-Vasco, M. M. Carralón-González, J. Aguareles-Gorines, E. M. Martí-Ballesteros, M. D. Sánchez-Manzano, D. Carnevali-Ruiz, M. García-Coca, R. Barrena-Puertas, R. García de Viedma, J. M. Luque-Pinilla, G. Sotres-Fernandez, J. M. Fernández-Sousa, X. E. Luepke-Estefan, J. A. López-Martín, J. M. Jimeno
Jazyk: angličtina
Rok vydání: 2022
Předmět:
Zdroj: Journal of Hematology & Oncology, Vol 15, Iss 1, Pp 1-4 (2022)
Druh dokumentu: article
ISSN: 1756-8722
DOI: 10.1186/s13045-021-01220-0
Popis: Abstract Background There is an urgent need for highly efficacious antiviral therapies in immunosuppressed hosts who develop coronavirus disease (COVID-19), with special concern for those affected by hematological malignancies. Case presentation Here, we report the case of a 75-year-old male with chronic lymphocytic leukemia who was deficient in CD19+CD20+ B-lymphocyte populations due to previous treatment with anti-CD20 monoclonal antibodies. The patient presented with severe COVID-19 pneumonia due to prolonged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and was treated with two courses of the antiviral plitidepsin on a compassionate use basis. The patient subsequently achieved an undetectable viral load, and his pneumonia resolved. Conclusions Treatment with plitidepsin was well-tolerated without any further hematological or cardiovascular toxicities. This case further supports plitidepsin as a potential antiviral drug in SARS-CoV-2 patients affected by immune deficiencies and hematological malignancies.
Databáze: Directory of Open Access Journals
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje